Government advisers are debating whether to recommend extra doses of the Pfizer vaccine, a key step toward the Biden administration's plan to dispense COVID-19 booster hots to most Americans
By MATTHEW PERRONE and LAURAN NEERGAARD Associated Press
September 17, 2021, 1:25 PM
• 4 min readShare to FacebookShare to TwitterEmail this article
WASHINGTON -- The Biden administration’s embattled plan to dispense COVID-19 booster shots to most Americans faced its first major hurdle Friday as a government advisory panel met to decide whether to endorse extra doses of the Pfizer vaccine.
Scientists inside and outside the government have been divided in recent days over the need for boosters and who should get them, and the World Health Organization has strongly objected to rich nations giving a third round of shots when poor countries don’t have enough vaccine for their first.
The panel, made up of outside experts who advise the Food and Drug Administration, weighed a less than clear-cut case: While research suggests immunity levels in those who have been vaccinated wane over time and boosters can reverse that, the Pfizer vaccine is still highly protective against severe illness and death, even amid the spread of the highly contagious delta variant.
The FDA experts were scheduled to vote on one basic question: Does the evidence show that a Pfizer booster would be safe and effective for people 16 and older? In the event of a yes vote, the FDA is expected to quickly approve boosters for Pfizer's shot.
But that is just one step in the process. The more thorny question of who should get the shots and when will be debated next week by advisers to the Centers for Disease Control and Prevention. The CDC generally adopts the group’s recommendations, which set policy for U.S. vaccination campaigns.
Some group members have made clear they favor giving third doses to older people, nursing home residents and front-line health care workers, rather than all adults.
Separate FDA and CDC decisions will be needed for people who received the Moderna or J&J shots can get boosters.
Friday’s meeting came as the delta variant continues to drive U.S. cases and deaths back to levels not seen since last winter. That has given urgency to efforts by top health officials to shore up Americans' protection against the virus.
Dr. Peter Marks, FDA’s top vaccine regulator, acknowledged the intense disagreements in opening remarks to the agency's advisory panel.
“We know there may be differing opinions in interpreting the data,” he said. “We strongly encourage all the different viewpoints to be voiced and discussed regarding the data which is complex and evolving.”
President Joe Biden’s top health advisers, including the heads of the FDA and CDC, first announced plans for widespread booster shots a month ago, targeting the week of Sept. 20 as an all-but-certain start date. It said boosters would be dispensed eight months after the second dose of the Pfizer and Moderna vaccines.
But that was before FDA staff scientists had completed their own assessments of the data. Some experts questioned whether Biden was breaking his own pledge to “follow the science” on COVID-19 by getting out ahead of government scientists.
Earlier this week, two top FDA vaccine reviewers joined a group of international scientists in publishing an editorial rejecting the need for boosters in healthy people. The scientists said continuing studies show the shots are working well despite the delta variant.
Pfizer was expected Friday to present data suggesting immunity from its vaccine begins to wane somewhere around six to eight months after the second dose.
The panel was also set to hear from Israeli health officials, who began offering boosters over the summer. Officials there tracked about 1 million people 60 and older and found that those who got the extra shot were far less likely to become infected soon afterward.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.